HTTP://WWW.COMPLIANCEONLINE.COM/IMPURITIES-IN-PHAR 2015 - Monitoring Impurities in Pharmaceutical Products - ICH Q3 requirements

Website http://bit.ly/18seT7c | Edit Freely

Category FDA GXP Compliance - Pharmaceuticals

Deadline: March 04, 2015 | Date: March 04, 2015

Venue/Country: Palo Alto, U.S.A

Updated: 2015-02-27 13:31:12 (GMT+9)

Call For Papers - CFP

Why Should You Attend:

Monitoring impurities is considered a critical activity of analytical development in order to ensure the quality of the pharmaceutical products. Current ICH Guidelines indicate that the measurement of impurities should always be conducted for active pharmaceutical ingredient (API) and its drug products.

Who Will Benefit:

To get the most out of the course, we highly recommended that you have at least two years of pharmaceutical analysis or drug development experience.

R&D analysts

QA and QC Managers

Regulatory scientists

Directors

Instructor Profile:

Kim Huynh-Ba, has almost 25 years of experience in analytical development, project management, strategic drug development and stability sciences. She is the Executive Director of Pharmalytik, where she provides consulting and training services to pharmaceutical companies including companies operating under FDA’s Consent Decree on harmonization and optimization of analytical best practices. Prior to this position, she was the Director of Pharmacopeial Education Department of U.S. Pharmacopeia (USP), where she was responsible for their education programs worldwide.

Use coupon code 232082 and get 10% off on registration.